Ken Griffin
TLX

Ken Griffin’s Telix Pharmaceuticals TLX Stock Holding History

Ken Griffin’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,998
Closed -$172K – 14586
2025
Q4 		$172K Buy
+22,998
New +$221K ﹤0.01% 11173
2025
Q3 		– Sell
-41,328
Closed -$668K – 14471
2025
Q2 		$668K Buy
+41,328
New +$694K ﹤0.01% 7948

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Ken Griffin's TLX Position: Q1 2026 in Review

Ken Griffin sold out of Telix Pharmaceuticals (TLX) in Q1 2026, closing a stake of 22,998 shares — an estimated $172K sold.

Ken Griffin first reported a position in TLX in Q2 2025 and held it in 2 quarters. The position peaked at $668K in Q2 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Ken Griffin reported no remaining Telix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 22,998 Telix Pharmaceuticals shares in Q1 2026, an estimated $172K.
  • Ken Griffin first reported a position in Telix Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Ken Griffin's Telix Pharmaceuticals position peaked at $668K in Q2 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.